Adaptive Radiotherapy for Genitourinary Cancers
Recruiting · NCT07324798 · Interventional (participants receive a specific treatment) · Lead sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The goal of this clinical trial is to learn if adaptive radiation boost works to treat genitourinary cancers, esp. in the context of prostate cancer patients with post-prostatectomy local relapse and bladder cancer patients with bladder-conserving treatment. It will also learn about the safety and efficacy of adaptive boost. The main questions it aims to answer are: Does adaptive boost lower the toxicities? Does adaptive boost maintain or improve the clinical efficacy? Participants will: Undergo adaptive boost on 1.5-Tesla MR-Linac Visit the clinic once every 2 weeks during RT, and every 3 months post-ART Keep a regular QOL questinnaire completion
Who can take part
Inclusion criteria
- Patients with newly diagnosed or metastatic/recurrent pathologically confirmed urological tumors, clinically assessed as suitable for adaptive radiotherapy;
- Age ≥ 18 years;
- ECOG performance status score 0-2;
- No prior radiotherapy history within the current radiation field;
- No contraindications for MRI scanning;
- No contraindications for radiotherapy.
Exclusion criteria
- Patients with contraindications to radiotherapy;
- Patients unable to tolerate MRI or with contraindications to MRI scanning.
Where it is running
1 location listed.
- Cancer Hospital, National Cancer Center, CAMS & PUMC - Beijing, Beijing Municipality, China